William Garrett Gray Sells 12,322 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CFO William Garrett Gray sold 12,322 shares of Checkpoint Therapeutics stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $4.05, for a total value of $49,904.10. Following the sale, the chief financial officer now directly owns 1,446,322 shares in the company, valued at $5,857,604.10. The trade was a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

William Garrett Gray also recently made the following trade(s):

• On Thursday, February 6th, William Garrett Gray sold 74,110 shares of Checkpoint Therapeutics stock. The shares were sold at an average price of $3.67, for a total transaction of $271,983.70.

Checkpoint Therapeutics Trading Up 0.4 %

Shares of CKPT stock traded up $0.02 on Tuesday, reaching $4.01. The company had a trading volume of 454,812 shares, compared to its average volume of 1,154,741. Checkpoint Therapeutics, Inc. has a 12 month low of $1.38 and a 12 month high of $4.50. The stock has a market cap of $335.47 million, a PE ratio of -2.18 and a beta of 1.21. The company has a 50-day moving average of $3.44 and a 200-day moving average of $3.34.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.47). The business had revenue of $0.04 million for the quarter. Sell-side analysts anticipate that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $4.80 price objective on shares of Checkpoint Therapeutics in a report on Monday, March 31st. Lake Street Capital restated a "hold" rating and set a $4.10 target price (down previously from $7.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $4.10 price target on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th.

Hedge Funds Weigh In On Checkpoint Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ameriflex Group Inc. bought a new stake in shares of Checkpoint Therapeutics in the fourth quarter valued at about $32,000. PUREfi Wealth LLC acquired a new stake in Checkpoint Therapeutics in the 4th quarter valued at approximately $32,000. SBI Securities Co. Ltd. bought a new stake in Checkpoint Therapeutics in the 4th quarter valued at approximately $32,000. Stifel Financial Corp acquired a new position in Checkpoint Therapeutics during the 4th quarter worth approximately $32,000. Finally, Tower Research Capital LLC TRC boosted its position in Checkpoint Therapeutics by 157.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company's stock worth $34,000 after acquiring an additional 6,486 shares during the last quarter. 22.00% of the stock is owned by institutional investors and hedge funds.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.